Symptoms of Perimenopause: What’s Normal and What Isn’t?

If you’ve noticed your body behaving differently—periods shifting, sleep going sideways, moods harder to predict—you’re not imagining it.

Many women move through months or years of change before menopause and aren’t told that this transition has a name: perimenopause. It can begin earlier than you expect, unfold in fits and starts, and affect nearly every system—hormones, yes, but also sleep, mood, joints, and cognition.

This guide explains when perimenopause typically begins, what’s happening biologically, and the most common symptoms women report. It also outlines when to check in with a healthcare professional and what kinds of treatments are available.

Our goal is straightforward: to give you clear, compassionate, evidence-informed information so you can recognize what you’re experiencing and feel confident discussing it with your clinician. Perimenopause is a normal phase. Understanding it is the first step to managing it well.

When Does Perimenopause Start?

Perimenopause is the transition leading up to menopause—the point when you have gone 12 consecutive months without a menstrual period. Most women notice perimenopausal changes in their mid‑40s, but the process can begin in the early 40s or not until the early 50s.¹

The length of this phase is highly individual. For many, it lasts 4–8 years, but shorter and longer courses are both normal—with women who begin the transition at a younger age often experiencing longer durations.²

Hormonally, perimenopause is characterized by fluctuation rather than a steady decline. The ovaries become less predictable, with cycles where ovulation is delayed or doesn’t occur. Estrogen levels can spike high and then fall low; progesterone tends to trend lower overall because of anovulatory cycles, though both hormones show considerable variability from cycle to cycle.^3,4,5 These shifts affect the brain, blood vessels, uterine lining, joints, and more—explaining why symptoms can be varied and seemingly unrelated.

Your experience will be shaped by multiple factors: genetics, smoking status, body weight, chronic health conditions (such as thyroid disease), and certain medications.^2,6 Some women have mild symptoms they barely register while others find daily life meaningfully disrupted. The range is wide, and your symptom pattern may evolve over time.

Common Symptoms of Perimenopause

Menstrual Irregularities

Changes in your menstrual cycle are often the first clear sign. You may notice:

• Shorter cycles (periods coming every 21–24 days) or longer gaps (35 days or more)

• Heavier bleeding, lighter bleeding, or a mix of both from month to month

• Skipped periods followed by a heavier or longer bleed

• Spotting between periods

These changes reflect fluctuating estrogen and lower, less consistent progesterone. When ovulation is delayed or absent, the uterine lining may build up longer under estrogen’s influence and then shed more heavily. In other cycles, lower estrogen can mean lighter flow.

Irregularity is common in perimenopause, but it shouldn’t be assumed to explain every change. Seek medical evaluation if you have:

• Very heavy bleeding (soaking through a pad or tampon every hour for several hours)

• Bleeding lasting more than 7–8 days

• Bleeding after sex

• Bleeding after 12 months without a period (postmenopausal bleeding)

• New bleeding patterns if you’re on hormone therapy or have an IUD

Your clinician may assess for anemia, thyroid issues, fibroids or polyps, and other causes. The bottom line: shifting cycles are expected, but persistent or dramatic changes warrant a check-in.

Hot Flashes and Night Sweats

Hot flashes (sudden warmth, flushing, and sweating) and night sweats are among the most recognized symptoms of perimenopause. They can feel like a wave of heat rising from the chest and face, often lasting 1–5 minutes, and may be followed by chills. Frequency ranges from occasional to multiple times per hour and often increases during stress or in warmer environments.

These symptoms affect quality of life, particularly when they disrupt sleep. Common triggers include hot beverages, alcohol, spicy food, smoking, and abrupt temperature changes. Practical strategies that can help include:

• Keeping your bedroom cool

• Dressing in layers

• Limiting alcohol and caffeine

• Practicing paced breathing

• Using stress-reduction techniques

If hot flashes are frequent or severe, discuss treatment options with your clinician. Hormone therapy is highly effective for reducing frequency and intensity of hot flashes.⁷

For women who cannot or prefer not to use hormone therapy, nonhormonal medications such as neurokinin receptor antagonists (like fezolinetant) have shown significant efficacy in reducing vasomotor symptoms.^8,9 Be sure to track patterns and triggers—they can guide both lifestyle adjustments and treatment decisions.

Sleep Disturbances

Sleep changes are common—even apart from night sweats. Some women have trouble falling asleep while others wake at 3 a.m. and can’t return to sleep.

Hormonal shifts interact with the brain’s sleep‑wake centers, and increased nighttime awakenings are typical in the late reproductive years. Research shows that the menopausal transition itself is associated with changes in sleep architecture—including increased sleep onset latency and physiological signs of hyperarousal—independent of hot flashes.^10,11 Factors such as nocturia (nighttime urination), anxiety, depression, and sleep-disordered breathing also contribute to sleep problems during this phase.^12,13

Over time, poor sleep can compound other symptoms: fatigue, lower frustration tolerance, mood volatility, and “brain fog.” Improving sleep hygiene is a useful first step: keep a consistent schedule, minimize late‑evening screens, avoid large meals and alcohol close to bedtime, and create a cool, dark sleep environment. If anxiety or ruminating thought loops are a barrier, cognitive behavioral strategies, relaxation techniques, or short-term therapy can help.

When sleep disturbances are persistent or impairing—especially if you snore loudly or gasp during sleep (possible sleep apnea)—seek evaluation. Treating hot flashes, addressing anxiety, or evaluating for sleep disorders can meaningfully improve overall well‑being.

Mood Changes and Anxiety

Irritability, heightened reactivity, new or worsening anxiety, and shifts in mood are frequently reported during perimenopause. You might notice quicker anger, tearfulness that feels “out of the blue,” or a baseline sense of unease.

These experiences are not imagined. Estrogen influences multiple neurotransmitter systems—including serotonin, norepinephrine, and GABA—that regulate mood, stress response, and emotional processing.^14,15 As estrogen fluctuates, so can your emotional equilibrium, with lower estradiol levels and hormonal variability associated with increased anxiety and depression.^16,17

Two points help orient care:

• Past history matters. If you’ve had a history of depression (including premenstrual or postpartum mood changes) or an anxiety disorder, you may be more sensitive to hormonal shifts.^18,19

• Context matters. Major life stressors, caregiving burdens, and sleep loss can amplify mood symptoms.

Your clinician can help differentiate transient, hormonally driven variability from a primary mood disorder that requires targeted treatment. Red flags include persistent sadness or anxiety most of the day for two weeks or more, loss of interest in usual activities, thoughts of self-harm, or significant impairment at work or home.

Effective treatments include psychotherapy, lifestyle interventions, targeted use of antidepressants or anxiolytics, and, for appropriate candidates, hormone therapy. You do not have to “tough it out”—timely support can prevent symptoms from becoming entrenched.

Joint Pain and Body Aches

Aches, stiffness, and new twinges—especially in the morning—are underrecognized parts of perimenopause. Estrogen has anti‑inflammatory effects and plays a role in connective tissue health,^20,21 and as levels fluctuate and trend downward, some women experience joint discomfort or generalized achiness.

The late menopausal transition appears to be a particularly vulnerable period for developing or worsening musculoskeletal pain.²² Symptoms may be most noticeable in hands, knees, hips, or the lower back.

Gentle, regular movement helps. Walking, strength training, and flexibility work can reduce stiffness and support joint function.

Evaluate persistent swelling, warmth, or pronounced pain with a clinician to rule out arthritis or other conditions. Treatment options range from lifestyle adjustments to physical therapy to medications, depending on severity and cause.

Genitourinary Symptoms (Vaginal and Urinary Changes)

Vaginal and urinary symptoms often emerge during perimenopause but are easy to overlook. Fluctuating—and eventually lower—estrogen affects the tissues of the vagina and urinary tract, leading to dryness, burning or itching, discomfort with intercourse, urinary urgency or frequency, and a tendency toward recurrent urinary tract infections. Some women also notice light spotting with intercourse due to tissue fragility.

Moisturizers used regularly and lubricants used during sex can ease dryness and discomfort. For persistent symptoms, low‑dose local vaginal estrogen is highly effective and generally well tolerated for many women, with studies showing significant improvements in sexual function, vaginal cytology, and quality of life.^23,24 It acts on urogenital tissues with minimal systemic absorption—resulting in only small, clinically insignificant increases in serum estradiol levels.^25,26

Pelvic floor physical therapy can also help with urinary urgency and pelvic discomfort. Seek care if symptoms are painful, recurrent, or accompanied by bleeding or infection.

Cognitive Changes

Many women describe “brain fog” as misplacing words, forgetting why they walked into a room, or feeling mentally slower. Concentration can be harder during periods of poor sleep or intense hot flashes.

These changes reflect multiple factors, including declining estradiol’s effects on hippocampal function and memory circuits, as well as compounding impacts of sleep disturbances, hot flashes, and psychological symptoms.^27,28,29

The reassuring truth is that for most, these changes are temporary and improve postmenopause, especially as sleep stabilizes and other symptoms are treated.^30,31,32

Support cognition by protecting sleep, exercising regularly, structuring your day to reduce multitasking, and using external memory aids. If cognitive changes are progressive, significant, or accompanied by neurological symptoms, seek medical evaluation.

When to See a Doctor

Make an appointment if symptoms are affecting your quality of life, if you’re uncertain whether changes are “normal,” or if you have any of the following:

• Very heavy bleeding, bleeding that lasts more than a week, or bleeding after 12 months without a period

• Severe or frequent hot flashes disrupting work or sleep

• Mood changes that interfere with daily function, persistent anxiety or depression, or any thoughts of self‑harm

• New headaches, chest pain, shortness of breath, or other concerning symptoms

• Signs of anemia (fatigue, paleness, shortness of breath with exertion)

Your clinician can rule out other conditions (thyroid dysfunction, anemia, fibroids, pregnancy), review medications, and discuss treatments.

Treatment options include hormone therapy for vasomotor and genitourinary symptoms in appropriate candidates, nonhormonal medications, localized vaginal estrogen for urogenital symptoms, and lifestyle strategies tailored to your needs.

Do not dismiss symptoms as “just aging.” With the right plan, most women find meaningful relief.

Moving Forward

Perimenopause is a universal transition, but the path through it is individual. Your symptoms are real, and there are tools to help.

Track what you’re experiencing—cycle changes, sleep, mood, hot flashes—and bring that information to your healthcare provider. Together, you can decide what to address first and which treatments fit your health history and preferences.

Knowledge turns uncertainty into action. Understanding the hormonal shifts behind your symptoms doesn’t make them vanish, but it does make them manageable—and that’s a meaningful difference day to day.

References

1.     Ahuja, M. (2016). Age of menopause and determinants of menopause age: A PAN India survey by IMS. Journal of Mid-Life Health, 7, 126-131. https://doi.org/10.4103/0976-7800.191012

2.     Paramsothy, P., Harlow, S., Nan, B., Greendale, G., Santoro, N., Crawford, S., Gold, E., Tepper, P., & Randolph, J. (2017). Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause, 24, 142–149. https://doi.org/10.1097/gme.0000000000000736

3.     Grub, J., Süss, H., Willi, J., & Ehlert, U. (2021). Steroid Hormone Secretion Over the Course of the Perimenopause: Findings From the Swiss Perimenopause Study. Frontiers in Global Women’s Health, 2. https://doi.org/10.3389/fgwh.2021.774308

4.     Grub, J., Willi, J., Süss, H., & Ehlert, U. (2024). The role of estrogen receptor gene polymorphisms in menopausal symptoms and estradiol levels in perimenopausal women – Findings from the Swiss Perimenopause Study. Maturitas, 183, 107942. https://doi.org/10.1016/j.maturitas.2024.107942

5.     McConnell, D., Crawford, S., Gee, N., Bromberger, J., Kazlauskaite, R., Avis, N., Crandall, C., Joffe, H., Kravitz, H., Derby, C., Gold, E., Khoudary, S., Harlow, S., Greendale, G., & Lasley, B. (2021). Lowered progesterone metabolite excretion and a variable LH excretion pattern are associated with vasomotor symptoms but not negative mood in the early perimenopausal transition: Study of Women’s Health Across the Nation. Maturitas, 147, 26-33. https://doi.org/10.1016/j.maturitas.2021.03.003

6.     Whitcomb, B., Purdue-Smithe, A., Szegda, K., Boutot, M., Hankinson, S., Hankinson, S., Manson, J., Rosner, B., Willett, W., Eliassen, A., & Bertone-Johnson, E. (2018). Cigarette Smoking and Risk of Early Natural Menopause. American Journal of Epidemiology, 187, 696–704. https://doi.org/10.1093/aje/kwx292

7.     Hadji, P., Schmeißer, J., Peters, K., & Göckeler-Leopold, E. (2024). Use of an estradiol transdermal spray in women with menopausal symptoms: a non-interventional study. Climacteric, 27, 473-481. https://doi.org/10.1080/13697137.2024.2376185

8.     Fraser, G., Lederman, S., Waldbaum, A., Kroll, R., Santoro, N., Lee, M., Skillern, L., & Ramael, S. (2020). A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause, 27, 382-392. https://doi.org/10.1097/gme.0000000000001510

9.  Santoro, N., Nappi, R., Neal-Perry, G., English, M., King, D., Yamaguchi, Y., & Ottery, F. (2024). Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Menopause, 31, 247-257. https://doi.org/10.1097/gme.0000000000002340

10.  Matthews, K., Lee, L., Kravitz, H., Joffe, H., Neal-Perry, G., Swanson, L., Evans, M., & Hall, M. (2021). Influence of the menopausal transition on polysomnographic sleep characteristics: A longitudinal analysis. Sleep, 44. https://doi.org/10.1093/sleep/zsab139

11.  Salin, S., Savukoski, S., Pesonen, P., Auvinen, J., & Niinimäki, M. (2023). Sleep disturbances in women with early-onset menopausal transition: a population-based study. Menopause, 30, 1106-1113. https://doi.org/10.1097/gme.0000000000002258

12.  Jones, H., Zak, R., & Lee, K. (2018). Sleep Disturbances in Midlife Women at the Cusp of the Menopausal Transition. Journal of Clinical Sleep Medicine, 14, 1127-1133. https://doi.org/10.5664/jcsm.7208

13.  Mirer, A., Young, T., Palta, M., Benca, R., Rasmuson, A., & Peppard, P. (2016). Sleep-disordered breathing and the menopausal transition among participants in the Sleep in Midlife Women Study. Menopause, 24, 157-162. https://doi.org/10.1097/gme.0000000000000744

14.  Vastagh, C., Rodolosse, A., Solymosi, N., & Liposits, Z. (2016). Altered Expression of Genes Encoding Neurotransmitter Receptors in GnRH Neurons of Proestrous Mice. Frontiers in Cellular Neuroscience, 10. https://doi.org/10.3389/fncel.2016.00230

15.  Göcz, B., Rumpler, É., Sárvári, M., Skrapits, K., Takács, S., Farkas, I., Csillag, V., Trinh, S., Bardóczi, Z., Ruska, Y., Solymosi, N., Póliska, S., Szőke, Z., Bartoloni, L., Zouaghi, Y., Messina, A., Pitteloud, N., Anderson, R., Millar, R., Quinton, R., Manchishi, S., Colledge, W., & Hrabovszky, E. (2022). Transcriptome profiling of kisspeptin neurons from the mouse arcuate nucleus reveals new mechanisms in estrogenic control of fertility. Proceedings of the National Academy of Sciences, 119. https://doi.org/10.1073/pnas.2113749119

16.  Hu, J., & He, L. (2025). Factors associated with anxiety and depression in perimenopausal women with abnormal uterine bleeding: A retrospective cohort study. BMC Psychology, 13. https://doi.org/10.1186/s40359-025-02853-3

17.  Saleh, S., Almadani, N., Mahfouz, R., Nofal, H., El-Rafey, D., & Seleem, D. (2024). Exploring the Intersection of Depression, Anxiety, and Sexual Health in Perimenopausal Women. International Journal of Women’s Health, 16, 1315-1327. https://doi.org/10.2147/ijwh.s464129

18.  Venborg, E., Osler, M., & Jørgensen, T. (2022). The association between postpartum depression and perimenopausal depression: A nationwide register-based cohort study. Maturitas, 169, 10-15. https://doi.org/10.1016/j.maturitas.2022.12.001

19.  Gordon-Smith, K., Perry, A., Di Florio, A., Craddock, N., Jones, I., & Jones, L. (2024). Associations between lifetime reproductive events among postmenopausal women with bipolar disorder. Archives of Women’s Mental Health, 28, 573-581. https://doi.org/10.1007/s00737-024-01533-2

20.  Yu, T., Zhang, D., Yang, Y., Jiang, Y., Wang, J., Li, J., Zhang, Y., Xie, R., & Hong, X. (2025). 17β estradiol activates autophagy and attenuates homocysteine mediated inflammation in endothelial cells through PI3K AKT MTOR signaling. Scientific Reports, 15. https://doi.org/10.1038/s41598-025-08797-3

21.  Lou, Y., Fu, Z., Tian, Y., Hu, M., Wang, Q., Zhou, Y., Wang, N., Zhang, Q., & Jin, F. (2023). Estrogen-sensitive activation of SGK1 induces M2 macrophages with anti-inflammatory properties and a Th2 response at the maternal–fetal interface. Reproductive Biology and Endocrinology, 21. https://doi.org/10.1186/s12958-023-01102-9

22.  Huang, F., Fan, Y., Tang, R., Xie, Z., Yang, L., Xie, X., Liang, J., & Chen, R. (2024). Musculoskeletal pain among Chinese women during the menopausal transition: findings from a longitudinal cohort study. Pain, 165, 2644-2654. https://doi.org/10.1097/j.pain.0000000000003283

23.  Pennacchini, E., Dall’Alba, R., Iapaolo, S., Marinelli, M., Palazzetti, P., Zullo, M., Cervigni, M., Morciano, A., Campanella, L., Ferraresi, B., & Schiavi, M. (2024). Treatment of Genitourinary Syndrome of Menopause in Breast Cancer and Gynecologic Cancer Survivors: Retrospective Analysis of Efficacy and Safety of Vaginal Estriol, Vaginal Dehydroepiandrosterone and Ospemifene. Journal of Menopausal Medicine, 30, 170-178. https://doi.org/10.6118/jmm.24011

24.  Gaspard, U., Taziaux, M., Jost, M., Bennink, H., Utian, W., Lobo, R., & Foidart, J. (2023). A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2—vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life. Menopause, 30, 480-489. https://doi.org/10.1097/gme.0000000000002167

25.  Mitchell, C., Larson, J., Crandall, C., Bhasin, S., LaCroix, A., Ensrud, K., Guthrie, K., & Reed, S. (2022). Association of Vaginal Estradiol Tablet With Serum Estrogen Levels in Women Who Are Postmenopausal. JAMA Network Open, 5. https://doi.org/10.1001/jamanetworkopen.2022.41743

26.  Pickar, J., Amadio, J., Bernick, B., & Mirkin, S. (2016). Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule. Climacteric, 19, 181-187. https://doi.org/10.3109/13697137.2015.1136926

27.  Jacobs, E., Weiss, B., Makris, N., Whitfield-Gabrieli, S., Buka, S., Klibanski, A., & Goldstein, J. (2016). Impact of Sex and Menopausal Status on Episodic Memory Circuitry in Early Midlife. The Journal of Neuroscience, 36, 10163-10173. https://doi.org/10.1523/jneurosci.0951-16.2016

28.  Hayashi, K., Ideno, Y., Nagai, K., Lee, J., Yasui, T., Kurabayashi, T., & Takamatsu, K. (2022). Complaints of reduced cognitive functioning during perimenopause: a cross-sectional analysis of the Japan Nurses’ Health Study. Women’s Midlife Health, 8. https://doi.org/10.1186/s40695-022-00076-9

29.  Zhu, C., Thomas, E., Li, Q., Arunogiri, S., Thomas, N., & Gurvich, C. (2023). Evaluation of The Everyday Memory Questionnaire-Revised in Menopausal Population: Understanding the Brain Fog During Menopause. medRxiv. https://doi.org/10.1101/2023.03.14.23287272++

30.  Than, S., Moran, C., Beare, R., Vincent, A., Lane, E., Collyer, T., Callisaya, M., & Srikanth, V. (2023). Cognitive trajectories during the menopausal transition. Frontiers in Dementia, 2. https://doi.org/10.3389/frdem.2023.1098693

31.  Page, C., Soreth, B., Metcalf, C., Johnson, R., Duffy, K., Sammel, M., Loughead, J., & Epperson, C. (2023). Natural vs. surgical postmenopause and psychological symptoms confound the effect of menopause on executive functioning domains of cognitive experience. Maturitas, 170, 64-73. https://doi.org/10.1016/j.maturitas.2023.01.007

32.  Tirkkonen, A., Kekäläinen, T., Aukee, P., Kujala, U., Laakkonen, E., Kokko, K., & Sipilä, S. (2021). Bidirectional associations between cognitive functions and walking performance among middle-aged women. Menopause, 29, 200-209. https://doi.org/10.1097/gme.0000000000001896